<- Go Home
Citius Oncology, Inc.
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York.Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
Market Cap
$72.7M
Volume
29.1K
Cash and Equivalents
N/A
EBITDA
N/A
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$49.00
52 Week Low
$0.85
Dividend
N/A
Price / Book Value
4.04
Price / Earnings
-3.53
Price / Tangible Book Value
4.04
Enterprise Value
$72.7M
Enterprise Value / EBITDA
N/A
Operating Income
-$18.9M
Return on Equity
85.28%
Return on Assets
-24.23
Cash and Short Term Investments
N/A
Debt
N/A
Equity
$17.0M
Revenue
N/A
Unlevered FCF
$7.1M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium